RNC Capital Management LLC Has $4.43 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

RNC Capital Management LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,336 shares of the medical research company’s stock after selling 118 shares during the quarter. RNC Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $4,425,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Halpern Financial Inc. grew its position in Thermo Fisher Scientific by 307.7% in the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management purchased a new position in Thermo Fisher Scientific in the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO purchased a new position in Thermo Fisher Scientific in the third quarter worth $38,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on TMO shares. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. HSBC started coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price target on the stock. Finally, TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $599.00.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last ninety days. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $579.37 on Thursday. The firm has a market capitalization of $220.92 billion, a P/E ratio of 37.50, a P/E/G ratio of 2.39 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $564.32 and its two-hundred day simple moving average is $519.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.40 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.